Extensive-Stage Small-Cell Lung Cancer Clinical Trial
Official title:
Phase 1b/2, Multicenter, Open-label Study of Carfilzomib, Carboplatin, and Etoposide in Subjects With Previously Untreated Extensive-stage Small-cell Lung Cancer
The purpose of this study is to determine the maximum tolerated dose and assess the safety, tolerability and activity of carfilzomib given in combination with carboplatin and etoposide as initial therapy for subjects with Extensive-Stage Small-Cell Lung Cancer (ES SCLC).
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04985851 -
To Evaluate the Efficacy of Durvalumab + Anlotinib in Terms of OS and PFS.
|
N/A | |
Recruiting |
NCT06223711 -
Durvalumab With Consolidative Radiochemotherapy and Ablative Stereotactic Radiotherapy in Oligometastatic ES-SCLC
|
Phase 2 | |
Active, not recruiting |
NCT05002868 -
Safety, Pharmacokinetics and Anti-tumor Activity of RP12146, in Patients With Solid Tumors
|
Phase 1 | |
Recruiting |
NCT04790253 -
PRophylactic Cerebral Irradiation or Active MAgnetic Resonance Imaging Surveillance in Small-cell Lung Cancer Patients (PRIMALung Study)
|
N/A | |
Recruiting |
NCT05572476 -
Lurbinectedin Combined With Durvalumab in Pre-treated Patients With Extensive Stage Small-cell Lung Cancer
|
Phase 2 | |
Recruiting |
NCT05874401 -
Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Topotecan
|
Phase 4 | |
Not yet recruiting |
NCT06008353 -
A Real-World Assessment of the Demographic, Clinical Characteristics and Outcomes of a Brazilian Cohort of Previously Untreated Extensive Stage-Small Cell Lung Cancer Receiving Durvalumab Combined With Platinum-Etoposide in (ES-SCLC) in Brazil
|
||
Recruiting |
NCT04947774 -
Prophylactic Cranial Irradiation in Extensive-stage Small Cell Lung Cancer
|
||
Completed |
NCT04902885 -
Phase 3 Study Evaluating Efficacy, Safety and Pharmacokinetics of Trilaciclib In Extensive-Stage Small Cell Lung Cancer Patients Receiving Carboplatin Combined With Etoposide or Topotecan
|
Phase 3 | |
Recruiting |
NCT05761977 -
Durvalumab in Combination With Standard Chemotherapy of Patients With Extensive Stage Small Cell Lung Cancer
|
||
Not yet recruiting |
NCT05765825 -
Study of Low-Dose Radiotherapy Concurrent Cisplatin/Carboplatin Plus Etoposide With Serplulimab for Patients With ES-SCLC
|
Phase 2 | |
Active, not recruiting |
NCT05092412 -
Low-dose Radiotherapy Combined With Durvalumab, Chemotherapy(EP) in the Treatment of ES-SCLC
|
Phase 2 | |
Not yet recruiting |
NCT06306560 -
A Study of Adebrelimab Combined With Famitinib and Chemotherapy in the Treatment of ES-SCLC.
|
Phase 2 | |
Active, not recruiting |
NCT04894591 -
To Assess the Effectiveness and Safety of Zepzelca in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC)
|
||
Recruiting |
NCT05280470 -
Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
|
Phase 2 | |
Not yet recruiting |
NCT06211036 -
Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab
|
Phase 3 | |
Completed |
NCT04878016 -
A Study of Carboplatin Plus Etoposide With or Without ZKAB001 (Anti-PD-L1 Antibody) in Patients With ES-SCLC
|
Phase 3 | |
Recruiting |
NCT04675697 -
Anlotinib Plus Platinum-etoposide in First-line of Extensive-stage Small-cell Lung Cancer
|
Phase 2 | |
Recruiting |
NCT05796089 -
Chemotherapy and Immunotherapy in Extensive-Stage Small-Cell Lung Cancer With Thoracic Radiotherapy
|
Phase 2 | |
Recruiting |
NCT05403723 -
Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC
|
Phase 1 |